Roche's big immune oncology hope atezolizumab shrinks certain bladder tumors
This article was originally published in Scrip
Executive Summary
Roche's atezolizumab, an anti-PDL1 treatment, shrinks tumors in people with a specific type of bladder cancer, according to data from the IMvigor 210 study. Roche highlighted atezolizumab at an analyst event on 31 May 2015, ahead of the annual ASCO meeting in Chicago. The company believes atezolizumab has the potential to provide a transformative benefit to a broad patient population either as a monotherapy or via combinations.